Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesCardiologyAetna Nesiritide Coverage & Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentAetnaPolicy 0709

    Nesiritide (Natrecor)

    Customize your policy alerts

    Sign up for Aetna Policy 0709 alerts

    Get alerted when Policy 0709 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity, investigational exclusions, and coding guidance for nesiritide (Natrecor) primarily for acute decompensated congestive heart failure and related settings; applies to Aetna members and providers submitting claims.

    Policy Summary
    PayerAetna
    PolicyNesiritide (Natrecor)
    Policy CodePolicy 0709
    Change TypeNo material clinical or coverage changes
    Effective DateAug 26, 2005
    Last ReviewSep 20, 2023
    Next Review DateAug 8, 2028
    Key ActionObtain prior authorization for nesiritide (HCPCS J2325) and document indication consistent with policy criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≤48
    max infusion hrs
    J2325HCPCS
    2001FDA approval
    7,141ASCEND‑HF N
    not reasonable/necessaryCMS stance

    Coverage Criteria for Nesiritide (Natrecor)

    inv-01: Initial use — Acute management

    Covered when ALL of the following are met:

    Acute decompensated CHF indication: Patient has acutely decompensated congestive heart failure with dyspnea at rest or with minimal activity

    Per policy medical necessity statement

    Setting: Use is for acute management in a hospitalized/acute care setting and not for intermittent outpatient or scheduled repetitive infusions

    Policy limits use to acutely decompensated patients; outpatient serial infusions are considered experimental/investigational

    Dosing limits: Dosing consistent with labeling (e.g., 2 µg/kg bolus then 0.01 µg/kg/min infusion) and infusion duration not longer than 48 hours<=48 hours

    Per FDA labeling and policy guidance

    inv-02: Coverage stance for acute decompensated heart failure

    Covered only in selected patients when ALL of the following are met:

    Primary diagnosis: Patient hospitalized with acutely decompensated heart failure with dyspnea at rest or with minimal activity (FDA‑approved indication)

    Support with clinical documentation linking to covered ICD-10 codes

    Prior therapy: Patient remains volume‑overloaded despite aggressive treatment with diuretics and/or vasodilators OR has intolerance/resistance to other vasodilators/diuretics

    Document prior therapies and responses; attempt other vasodilators/diuretics prior to nesiritide

    Specialty input: Use considered with cardiology/subspecialty consultation due to modest benefit and risk of hypotension

    Recommended prior to routine use

    inv-03: Peri-operative cardiovascular surgery / renal protection

    Use for peri-operative renal protection is investigational/limited evidence and may be considered only in research or select high-risk settings when documentation supports anticipated benefit:

    Evidence summary: Randomized trials and pooled analyses report inconsistent effects on renal and clinical end points; some trials found reduced immediate postoperative AKI but no reduction in dialysis or long‑term mortality

    Insufficient evidence to support routine peri-operative use

    Consideration criteria: Patient is undergoing high‑risk cardiovascular surgery and clinician documents rationale citing potential immediate renal protection and lack of alternative proven therapies; use preferably in context of a clinical trial or with cardiology/renal consultation

    Document informed decision‑making and anticipated benefit

    inv-04: Low-dose nesiritide for acute HF with renal dysfunction (ROSE trial findings)

    Not supported for routine addition to diuretic therapy to enhance decongestion or preserve renal function:

    Trial evidence: ROSE randomized trial (360 hospitalized patients with acute HF and renal dysfunction) showed low‑dose nesiritide had no significant effect on 72‑hour urine volume or change in cystatin C compared with placebo and no benefit on secondary decongestion or renal outcomes

    Do not use routinely for this purpose

    The policy excludes use of nesiritide for intermittent infusion in persons who are not acutely decompensated and for scheduled repetitive use (for example outpatient “tune‑up” infusions). The policy also lists use to enhance diuresis, to improve renal function, for prophylactic prevention of acute kidney injury, as adjuvant therapy following cardiac surgery (eg, after Fontan surgery), and other non‑label indications as experimental/investigational and excluded from coverage.

    Meta-analyses and expert reviews cited in the policy support restricting nesiritide to hospitalized patients with acutely decompensated CHF, and therefore these outpatient or serial infusion applications are not supported by evidence of clinical benefit.

    Nesiritide is contraindicated in persons with hypersensitivity to any of its components. Per the FDA‑approved labeling and the policy, it should not be used as primary therapy for cardiogenic shock or in patients with a systolic blood pressure < 90 mm Hg.

    Use in these settings may lead to denial of coverage and carries potential for clinical harm (eg, worsening hypotension); documentation of contraindications should be reviewed prior to authorization.

    The policy states that routine outpatient or broad population use of nesiritide for acute heart failure is not recommended. Evidence from large trials and guideline reviews found only modest, inconsistent symptomatic benefit and raised safety concerns, so nesiritide should be reserved for selected hospitalized patients rather than used routinely across the general heart‑failure population.

    Guidance highlighted in the policy recommends attempting standard vasodilators and/or diuretics before considering nesiritide and involving subspecialty consultation when use is contemplated.

    Clinical Policy Bulletins are developed to assist in administering plan benefits and are informational. They contain a general description of plan coverage considerations but do not constitute a contract or guarantee of benefits. Treating providers remain responsible for medical advice and treatment decisions; policies may be updated and are subject to change.

    Serial outpatient or intermittent nesiritide infusions for patients with chronic or stage C/D heart failure have not demonstrated clinical benefit and are not medically necessary. The FUSION II trial and related studies showed no reduction in death or hospitalizations with scheduled outpatient infusions, and the policy therefore does not support routine outpatient infusion programs.

    Outpatient “tune‑up” use (eg, weekly 4–8 hour infusions) for chronic decompensated HF is specifically identified as unsupported and considered experimental/investigational when not part of an approved trial.

    Empiric peri‑operative administration of nesiritide to improve early postoperative outcomes (for example, after Fontan surgery) is not supported by the evidence. A randomized trial comparing peri‑operative nesiritide, milrinone, and placebo after Fontan found no significant improvement in days alive and out of hospital or other early clinical outcomes with nesiritide.

    Accordingly, routine empiric peri‑operative use for early postoperative benefit is considered experimental/investigational and is not covered outside of research or clearly documented, exceptional circumstances.

    Coding and Duration Guidance

    Maximum infusion duration
    Maximum infusion durationNo longer than 48 hours

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization for J2325 — Document Indication

    Prior authorization required for nesiritide (HCPCS J2325) when used for acute decompensated congestive heart failure. Documentation must support the indication (acute decompensated CHF with dyspnea at rest or with minimal activity) and link to covered ICD-10 codes.

    • Prior authorization required for J2325 when selection criteria are met.
    • Medical record must document acute decompensated CHF with dyspnea at rest or with minimal activity.
    Step Therapy

    Prioritize Other Therapies Before Nesiritide

    Reserve nesiritide for patients who remain volume overloaded despite aggressive diuresis and/or vasodilator therapy. Use should be considered only after other standard therapies have been attempted.

    • Attempt aggressive diuretics and vasodilators before nesiritide.
    • Consider subspecialty (cardiology) consultation when using nesiritide.

    Background and Rationale

    Nesiritide is a recombinant form of human B‑type natriuretic peptide (Natrecor) approved by the FDA for intravenous use to provide early relief of dyspnea in patients hospitalized with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity. The labeled regimen (commonly referenced in the policy) includes a 2 µg/kg bolus followed by a 0.01 µg/kg/min infusion for up to 48 hours.

    Clinical trial data summarized in the policy show nesiritide can modestly improve shortness of breath but have not demonstrated improvements in mortality or hospital length of stay, and safety signals (including possible renal effects and hypotension) prompted label revisions and expert recommendations to limit use to hospitalized acutely decompensated patients.

    Definitions and Key Terms

    inv-28: Nesiritide (Natrecor) — recombinant human B-type natriuretic peptide definition and approved use.
    DefinitionRecombinant form of endogenous human B-type (brain) natriuretic peptide (BNP).
    FDA-approved indicationIntravenous use for treatment of acutely decompensated congestive heart failure with dyspnea at rest or with minimal activity (approved August 2001).
    Physiologic actionsDecreases cardiac filling pressures, increases cardiac index, and can improve dyspnea and hemodynamic congestion.
    Dosing noteLabeling recommends IV bolus 2 µg/kg followed by infusion 0.01 µg/kg/min (see maximum duration limit).
    inv-29: Acute decompensated CHF — definition involving dyspnea at rest or with minimal activity requiring hospitalization and parenteral therapy.
    Clinical definition
    Policy Summary
    PayerAetna
    PolicyNesiritide (Natrecor)
    Policy CodePolicy 0709
    Change TypeNo material clinical or coverage changes
    Effective DateAug 26, 2005
    Last ReviewSep 20, 2023
    Next Review DateAug 8, 2028
    Key ActionObtain prior authorization for nesiritide (HCPCS J2325) and document indication consistent with policy criteria.
    SourceLink
    On This Page
    Coverage Criteria for Nesiritide (Natrecor)Coding and Duration GuidanceProvider Actions, Prior Authorization, and DocumentationBackground and RationaleDefinitions and Key Terms
    Note

    Consider Alternatives Before Nesiritide

    Providers should consider alternative treatments (diuretics, vasodilators) and the availability of alternatives prior to using nesiritide. Nesiritide may be considered when alternatives are ineffective, not tolerated, or contraindicated.

    • Consider nitroglycerin, other vasodilators, and diuretics first.
    • Document prior therapy attempts and reasons nesiritide is being selected.
    Denial Risk

    Experimental/Investigational Uses — Not Covered

    Use of nesiritide outside the acute management of acutely decompensated CHF with dyspnea at rest or with minimal activity (for example, intermittent outpatient infusions, scheduled repetitive use, enhancement of diuresis, improvement of renal function, prophylactic use to prevent acute kidney injury, adjuvant post‑cardiac surgery) is considered experimental/investigational and is not covered.

    • Intermittent outpatient infusions and scheduled repetitive use — experimental/investigational.
    • Use to enhance diuresis or improve renal function — experimental/investigational.
    • Peri-operative administration and subcutaneous BNP — experimental/investigational.
    Denial Risk

    Contraindications — Denial Risk if Used Inappropriately

    Nesiritide is contraindicated as primary therapy in cardiogenic shock and should not be used in patients with systolic blood pressure < 90 mm Hg. Hypersensitivity to components of nesiritide is a contraindication. Use in these situations may result in denial.

    • Do not use as primary therapy for cardiogenic shock.
    • Do not administer if systolic BP < 90 mm Hg.
    • Document absence of contraindications in the medical record.
    Denial Risk

    Restricted Routine Use — Limit to Selected Patients

    Routine use of nesiritide in broad populations of patients with acute heart failure is not recommended. Limit use to selected patients meeting policy criteria and document rationale when used outside typical settings.

    • Not recommended for routine or standard use in all patients with acute HF.
    • Reserve for selected patients meeting clinical criteria and after other therapies tried.
    Documentation Required

    Required Clinical Documentation

    Medical records must clearly support the diagnosis of acute decompensated CHF with dyspnea at rest or with minimal activity and include documentation of prior therapy attempts (diuretics, vasodilators), clinical findings of volume overload if present, and linkage to appropriate ICD-10 codes.

    • Document dyspnea at rest or with minimal activity and acute decompensation.
    • Record prior diuretic/vasodilator therapy and response or intolerance.
    • Include covered ICD-10 codes (e.g., I50.21, I50.23, I50.31, I50.33, I50.41, I50.43).
    Note

    This Section Contains Policy History and Administrative Notices

    Policy history, review dates, and administrative notices are provided in the policy header and history section. Providers should refer to the policy history for the last review date, effective date, and next review date.

    • Effective: 08/26/2005
    • Last Review: 09/20/2023
    • Next Review: 08/08/2028
    Step Therapy

    Step Therapy Status Note — No Step Therapy Requirements Stated

    No formal step therapy requirements are specified in this policy for nesiritide; however, clinical guidance and external guidelines recommend attempting vasodilators and/or diuretics other than nesiritide prior to trialing nesiritide.

    • Policy does not impose an explicit step therapy program.
    • Clinical practice guidance recommends trying alternatives before nesiritide.
    Heart failure with sudden worsening of symptoms such as dyspnea at rest or with minimal activity requiring hospitalization and parenteral therapy.
    Typical presentationPatients present with increased ventricular wall tension, volume overload and shortness of breath leading to hospital admission.
    Treatment contextIndication for therapies including IV nesiritide when dyspnea at rest or minimal activity is documented and other therapies considered.
    inv-30: Acutely decompensated heart failure (ADHF) — hospitalized HF description for which nesiritide is FDA-approved as IV option.
    ADHF descriptionHospitalized heart failure with dyspnea at rest or with minimal activity for which nesiritide is FDA-approved as an intravenous option to relieve dyspnea.
    Evidence summaryLarge randomized trials (eg, ASCEND-HF, 7,141 patients) showed modest symptom improvement but no reduction in mortality or rehospitalization; increased hypotension risk noted.
    Use considerationsReserve for selected hospitalized patients (eg, volume-overloaded despite diuretics/vasodilators or intolerant/resistant to other agents) often with subspecialty input.
    inv-31: Acute kidney injury (AKI) definition used in Ejaz trial — absolute increase in serum creatinine >= 0.3 mg/dL or >= 50% increase from baseline within 48 hours.
    AKI definition (Ejaz trial)Absolute increase in serum creatinine ≥ 0.3 mg/dL OR ≥ 50% increase from baseline within 48 hours.
    Trial contextDefinition used in a randomized trial of prophylactic nesiritide in 94 high-risk cardiac surgery patients (Ejaz et al., 2009).
    Outcome relevanceEjaz trial found fewer patients meeting this AKI definition with nesiritide versus control, but no reduction in dialysis or mortality.
    inv-32: Nesiritide (Natrecor) references and review history note.
    Selected referencesPolicy references include key reviews and trials (eg, Wylie & Tsao 2004; Xiong et al. 2015; Yancy et al.; FUSION II; ASCEND-HF cited elsewhere).
    Policy historyPolicy effective date: 08/26/2005; Last review: 09/20/2023; Next review: 08/08/2028.
    Review focusReferences and review history pertain to clinical evaluation of nesiritide in acute decompensated HF and outpatient infusion settings.